Cargando…
Metronomic chemotherapy: changing the paradigm that more is better
The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669231/ https://www.ncbi.nlm.nih.gov/pubmed/19370174 |
_version_ | 1782166245146099712 |
---|---|
author | Scharovsky, O.G. Mainetti, L.E. Rozados, V.R. |
author_facet | Scharovsky, O.G. Mainetti, L.E. Rozados, V.R. |
author_sort | Scharovsky, O.G. |
collection | PubMed |
description | The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer. |
format | Text |
id | pubmed-2669231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-26692312009-04-14 Metronomic chemotherapy: changing the paradigm that more is better Scharovsky, O.G. Mainetti, L.E. Rozados, V.R. Curr Oncol Medical Oncology The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer. Multimed Inc. 2009-03 /pmc/articles/PMC2669231/ /pubmed/19370174 Text en 2009 Multimed Inc. |
spellingShingle | Medical Oncology Scharovsky, O.G. Mainetti, L.E. Rozados, V.R. Metronomic chemotherapy: changing the paradigm that more is better |
title | Metronomic chemotherapy: changing the paradigm that more is better |
title_full | Metronomic chemotherapy: changing the paradigm that more is better |
title_fullStr | Metronomic chemotherapy: changing the paradigm that more is better |
title_full_unstemmed | Metronomic chemotherapy: changing the paradigm that more is better |
title_short | Metronomic chemotherapy: changing the paradigm that more is better |
title_sort | metronomic chemotherapy: changing the paradigm that more is better |
topic | Medical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669231/ https://www.ncbi.nlm.nih.gov/pubmed/19370174 |
work_keys_str_mv | AT scharovskyog metronomicchemotherapychangingtheparadigmthatmoreisbetter AT mainettile metronomicchemotherapychangingtheparadigmthatmoreisbetter AT rozadosvr metronomicchemotherapychangingtheparadigmthatmoreisbetter |